Temsirolimus
Mammalian Target Of Rapamycin (Mtor) Kinase Inhibitors
Sold as TORISEL
- Drug class
- Mammalian Target Of Rapamycin (Mtor) Kinase Inhibitors
- Availability
- See label
- Routes
- Intravenous
- Markets covered
- 3
- Products on record
- 3
Overview
Temsirolimus is an active pharmaceutical ingredient in the Mammalian Target Of Rapamycin (Mtor) Kinase Inhibitors group (L01EG). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| CA Canada | Health Canada | 1 | March 22, 2025 |
| EU European Union | EMA | 1 | March 3, 2025 |
| GB United Kingdom | MHRA | 1 | January 16, 2026 |
CACanada· Health Canada
1 product
Uses
TORISEL (temsirolimus for injection) is indicated for the treatment of metastatic renal cell carcinoma. 1 Pediatrics Pediatrics (1 year – 21 years): There is no indication for the use of TORISEL in the pediatric population. 3 Pediatrics).
4 Geriatrics). Overall survival in a subset of patients 65 years of age or older (N=64) treated with TORISEL was shorter than that observed with patients under 65 years of age (see 14 CLINICAL TRIALS). The clinical relevance of this subgroup analysis is unclear.
No specific dose adjustment is recommended for elderly patients.
How to take
EUEuropean Union· EMA
1 product
Uses
1). 1).
How to take
GBUnited Kingdom· MHRA
1 product
1 product on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [3].
Drug interactions
Known interactions involving Temsirolimus. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 473. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]Health Canada (DPD) · 02304104 · revised March 22, 2025
- [2]European Medicines Agency · EMEA/H/C/000799 · revised March 3, 2025
- [3]MHRA (UK) · PLGB000571645 · revised January 16, 2026
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.